Tower Research Capital LLC (TRC) - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 61 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$10,0000.0%40,338
+103.7%
0.00%
Q2 2022$10,000
-47.4%
19,807
+109.9%
0.00%
Q1 2022$19,000
+58.3%
9,438
+247.6%
0.00%
Q4 2021$12,0000.0%2,715
+109.5%
0.00%
Q3 2021$12,000
-36.8%
1,296
+26.8%
0.00%
Q2 2021$19,000
+216.7%
1,022
-40.4%
0.00%
Q1 2021$6,0001,7150.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q4 2021
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders